Risperidone: A Commentary on Drug Profiling

Author(s): Felix-Martin Werner*, Rafael Coveñas.

Journal Name: Current Drug Discovery Technologies

Volume 16 , Issue 3 , 2019

Become EABM
Become Reviewer

Keywords: Anti-cancer agent, antipsychotic drug, bupropion, drug reprofiling, risperidone, aggressive behaviour.

[1]
Dilly SJ, Morris GS. Pimping up drugs. Recovered, superannuated and under exploited drugs - An introduction to the basics of drug reprofiling. Curr Drug Discov Technol 2014; 14: 121-6.
[2]
Banerja U, Workan P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin Oncol 2016; 43: 436-45.
[3]
Newmann DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-35.
[4]
Berigan TR. The many uses of bupropion and bupropion sustained release (SR) in adults. Prim Care Companion J Clin Psychiatry 2002; 4: 30-2.
[5]
Stafford RS. Regulating off-label drug use – Rethinking the role of the FDA. N Engl J Med 2008; 358: 1427-9.
[6]
Curtis FR, Fairman KA. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department. J Manag Care Pharm 2009; 15: 2.
[7]
Tseng S, Pak G, Washenik K, Pomeranz M, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-79.
[8]
Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-77.
[9]
England P. Infringement of second medical use patents in Europe. J Intellect Property Law Pract 2016; 11: 426-34.
[10]
Liua M, Croixb SL. A cross-country index of intellectual property rights in pharmaceutical inventions. Res Policy 2015; 44: I206-16.
[11]
Dilly SJ, Stoloff G, Taylor PC. Modulators of androgen synthesis. US patent 9, 072, 743 2015.
[12]
Even R. Drug and biological development: From molecule to product patent and beyond. Springer Science & Business Media New York 2007.
[13]
Higgins G. Risperidone: Will it significantly change schizophrenia therapy? Inpharma Wkly 1993; 892: 5-6.
[14]
Scahill L, Koenig K, Carroll DH, Pachlet M. Risperidone approved for the treatment of serious behavioral problems in children with autism. J Child Adolesc Psychiatr Nurs 2007; 20: 188-90.
[15]
Isaac G. Risperidone use in children: gynecomastia, hyperprolactinemia, and other controversies. Psychiatr Ann 2015; 45: 204-11.
[16]
Breitbart W, Alici Y. Evidence based treatment of delirium in patients with cancer. J Clin Oncol 2012; 30: 1206-14.
[17]
Okamoto Y, Tsuneto S, Matsuda Y, et al. Retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage 2007; 34: 217-22.
[18]
Kracke EF, Tosh AK. Treatment of anorexia nervosa with long term risperidone in an outpatient setting. Springerplus 2014; 3: 706.
[19]
Friedman JH. Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warning. Neurology 2006; 67: 564-6.
[20]
Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobioloy of schizophrenia. CNS Drugs 2006; 20: 398-409.
[21]
Rauschenberger K, Scholer K, Sass JQ, et al. A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival. EMBO Mol Med 2009; 2: 166.
[22]
Carlson E, Marquez R, Du F, Wang Y, Xu L, Van S. Overexpression of 17beta- hydroxysteroid dehydrogenase type 10 increase pheocytoma cell growth and resistance to cell death. BMC Cancer 2015; 15: 166.
[23]
Lamb R, Harrison H, Hulit J, Smith D, Lisanti M, Sotgia F. Mitochondria as new therapeutic targets for eradiating cancer stem cells: Quatitative protemics and functional validation via MCT1/2 inhibition. Oncotarget 2014; 5: 11029-37.
[24]
Jensen GL. Drug-induced hyperphagia: What can we learn from psychiatric medications? J Parenter Enteral Nutr 2008; 32: 578-81.
[25]
Migliaccio A, Varricchio L, De Falco A, et al. Inhibition of SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene 2008; 26: 6619-29.
[26]
Dilly SJ, Stoloff G, Taylor PC. Modulators of androgen synthesis. US patent 9, 375, 433 2016.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2019
Page: [315 - 316]
Pages: 2
DOI: 10.2174/157016381603191014171046

Article Metrics

PDF: 18
HTML: 4